Company
Headquarters: Taipei, Taiwan
CEO: Dr. Yue-Teh Jang
TW$4.75 Billion
TWD as of July 1, 2024
US$145.7 Million
| Company | Market Cap (USD) |
|---|---|
| Intuitive | $154.23 B |
| EssilorLuxottica SA | $98.99 B |
| Becton, Dickinson and Company | $65.82 B |
| Alcon Inc. | $43.72 B |
| HOYA Corp | $42.76 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Medeon Biodesign, Inc. develops and markets medical device solutions in Taiwan. It focuses on developing devices for minimally invasive surgeries, such as Duett, a vascular graft system; ClickClean, a solution to view throughout laparoscopic surgeries; AbClose to prevent port site herniation caused by improper closure; UroCross, an expander system; PUMA, a solution to treat orthopedic extremity injuries; and Cross-Seal, a large-bore closure device. The company was founded in 2012 and is headquartered in Taipei, Taiwan.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Medeon Biodesign, Inc. has the following listings and related stock indices.
Stock: TWSE: 6499 wb_incandescent